DUBLIN – Faron Pharmaceuticals Oy said it hopes to get its flagship program in acute respiratory distress syndrome (ARDS) back on track, following the Yoda pharmacokinetic/pharmacodynamic study of Traumakine (recombinant human interferon-beta 1a) in human volunteers, which demonstrated that concomitant administration of corticosteroids blocked the drug's action.